Gepirone-ER Treatment of Low Sexual Desire Associated with Depression in Women as Measured by the DeRogatis Inventory of Sexual Function (DISF) Fantasy/Cognition (Desire) Domain—A Post Hoc Analysis

Fabre, Louis F.; Smith, Louis C.; Derogatis, Leonard R.

doi:10.1111/j.1743-6109.2011.02330.x

Cited by 12 publications

(9 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results presented here constitute a fairly complete analysis of the effect of depression on a [19][20][21][22]. Group C = vertical dash pattern = severe depression (HAMD-17 [23][24][25].…”

Section: Discussionmentioning

confidence: 99%

“…The presence of sexual dysfunction was not an entry criterion for any of these studies. While sexual function measures were employed, this was not the focus of the investigations and, as a result, did not cause a high placebo response in measures of sexual function [21]. Generally, the population is made of women with an average age of 38 years old, 85% premenopausal and 81% white.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Major Depression on Sexual Function in Women

Fabre¹,

Smith²

2012

The Journal of Sexual Medicine

Self Cite

View full text Add to dashboard Cite

Introduction Eleven hundred eighty-four depressed women were entered into five short-term (8 weeks) studies of gepirone-extended release (ER) vs. placebo for treatment of major depressive disorder (MDD) (134001, 134002, and 134017), or atypical depressive disorder (ADD) (134004 and 134006). The effect of depression on sexual function was examined prior to treatment. Aim To determine the effect of depression on the prevalence of Diagnostic and Statistical Manual Fourth Edition (DSM-IV) sexual dysfunction diagnoses and the Derogatis Inventory of Sexual Function (DISF) total score and domain scores and to measure the effect of severity of depression. Main Outcome Measures Hamilton Depression Rating Scale (HAMD-17), DSM-IV diagnoses, and DISF total and domain scores. Methods DSM-IV diagnoses—hypoactive sexual desire disorder (HSDD), sexual aversion disorder (SAD), female arousal disorder (FAD), and female orgasmic disorder (FOD)—were made by a trained psychiatrist. The HAMD-17 measured antidepressant efficacy. The DISF or its self-report version measured sexual function. To access the effect of severity of depression, baseline HAMD-17 scores were stratified as mild (<18), moderate (19–22), severe (23–25), or extreme (26–33). All measures were taken at baseline. Results In this depressed female population, prevalence rates were HSDD 17.7%, SAD 3.4%, FAD 5.8%, and FOD 7.7%. These rates for females are within the reported normal (nondepressed) values. However, DISF scores are one or more standard deviations below population norms for total score. DISF domains are not equally affected: orgasm is most impaired, while sexual desire and sexual arousal are somewhat preserved. Higher HAMD scores result in lower DISF scores (greater sexual dysfunction). Conclusions In women, depression affects DISF scores more than DSM-IV diagnoses for sexual dysfunction. With increasing severity of depression (increased HAMD scores), sexual dysfunction becomes greater (lower DISF scores). For equal HAMD scores, DISF scores for MDD and ADD are the same.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Effect of Major Depression on Sexual Function in Women

Fabre¹,

Smith²

2012

The Journal of Sexual Medicine

Self Cite

View full text Add to dashboard Cite

show abstract

“…5HT 1A antagonism (Moreau et al ., ) and agonism (Brunelli et al ., ) have been shown to both be anxiolytic and anxiogenic in different models (Table ). While this probably suggests the presence of unknown interactions that modify the action at 5HT 1A , it is notable that buspirone and gepirone, 5HT 1A partial agonists, can improve both anxiety and depression (Robinson et al ., ; Yocca, ; Amsterdam, ; Fabre et al ., ). Some of the SGAs have partial agonist actions at 5HT 1A .…”

Section: Guiding Principle I: All Sgas May Have Anxiolytic Effectsmentioning

confidence: 97%

Antipsychotics as antidepressants

Roberts

Lohano

El‐Mallakh

2015

Asia-Pacific Psychiatry

View full text Add to dashboard Cite

Three second-generation antipsychotic (SGA) agents have received FDA approval for adjunctive treatment, to antidepressant, of major depressive disorder: quetiapine, aripiprazole, and olanzapine. Additionally, quetiapine and lurasidone have been approved for the treatment of bipolar depression. There are data suggesting that quetiapine is effective for major depressive disorder as monotherapy. These agents are effective for depression only at subantipsychotic doses. Receptor profiles predict that all SGA will have anxiolytic effects as subantipsychotic doses but that all will be dysphorogenic at full antipsychotic doses (i.e., produce a depression-like clinical picture). The antidepressant effect appears to be unique to some agents, with direct evidence of insignificant antidepressant action for ziprasidone. Three general principles can guide the use of antipsychotics as antidepressants: (i) All SGAs may have anxiolytic effects; (ii) full antipsychotic doses are dysphorogenic, and therefore, subantipsychotic doses are to be used; and (iii) SGAs do not have a general antidepressant effect, rather, this appears to be unique to quetiapine and aripiprazole, and possibly lurasidone.

show abstract

“…In premenopausal women, gepirone‐ER has shown efficacy in a depressed population as measured by reversing the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM‐IV) diagnosis of hypoactive sexual desire disorder (HSDD) [24]. Gepirone‐ER has also shown efficacy in improving DeRogatis Inventory of Sexual Function (DISF) scores in both short‐term and longer‐term studies in populations of depressed women [25].…”

Section: Introductionmentioning

confidence: 99%

“…An examination of the effect of gepirone‐ER on sexual function in women indicated that there are three components to its therapeutic profile: an antidepressant effect, an anxiolytic effect, and a pro‐sexual effect [25]. The combination of these three effects results in a statistically significant improvement in sexual function in women in both short‐term and long‐term studies.…”

Section: Introductionmentioning

confidence: 99%

The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men

Fabre¹,

Clayton

Smith³

et al. 2012

The Journal of Sexual Medicine

Self Cite

View full text Add to dashboard Cite

Introduction Sexual dysfunction is common in patients with major depressive disorder (MDD). Antidepressant medications especially the selective serotonin reuptake inhibitors (SSRIs) may improve depressive symptoms but further decrease sexual function. Gepirone extended release (gepirone-ER) differs from the SSRIs in only affecting the 5-HT1A receptor and has demonstrated efficacy in treatment of depression and sexual dysfunction in depressed women. This report describes the effect of gepirone-ER on sexual function in depressed men. Aim The aims of this article were to study the effects of gepirone-ER on sexual function in men with MDD and to determine if positive effects are independent of antidepressant or anxiolytic activity. Main Outcome Measures The main outcome measures of this article were Hamilton depression rating scale (HAMD-17), and changes in sexual functioning questionnaire (CSFQ). Methods In an 8-week study, gepirone-ER, placebo, or fluoxetine were administered in a double-blind fashion to 181 depressed men. The CSFQ results were used to determine quality of sexual function. To test for an antidepressant or anxiolytic effect, a 50% reduction in HAMD-17 score separated antidepressant responders from nonresponders, and item 12 of the HAMD scale (psychic anxiety) scores of 0 or 1 separated anxiolytic responders from nonresponders. Results Gepirone-ER treatment improved total sexual function compared with placebo measured by the CSFQ at weeks 4 (P = 0.012) and 8 (P = 0.046). At 4 weeks, almost every CSFQ domain is improved. The orgasm domain was especially improved, 67% by week 4. Gepirone-ER antidepressant and anxiolytic nonresponders showed significant improvement in sexual function. Fluoxetine treatment did not produce improvement. In fact, fluoxetine-treated subjects had lower scores on the total CSFQ, less than placebo, and significantly less than gepirone-ER. Conclusion Gepirone-ER improves sexual dysfunction in depressed men. All domains of sexual function improved. Gepirone-ER has a pro-sexual effect independent of antidepressant or anxiolytic activity.

show abstract

Gepirone-ER Treatment of Low Sexual Desire Associated with Depression in Women as Measured by the DeRogatis Inventory of Sexual Function (DISF) Fantasy/Cognition (Desire) Domain—A Post Hoc Analysis

Cited by 12 publications

References 27 publications

The Effect of Major Depression on Sexual Function in Women

The Effect of Major Depression on Sexual Function in Women

Antipsychotics as antidepressants

The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men

Contact Info

Product

Resources

About